These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 33142238

  • 1. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS.
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [Abstract] [Full Text] [Related]

  • 2. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y, Zhou L, Safran H, Borsuk R, Lulla R, Tapinos N, Seyhan AA, El-Deiry WS.
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [Abstract] [Full Text] [Related]

  • 3. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS.
    Mol Cancer; 2015 May 01; 14():99. PubMed ID: 25927855
    [Abstract] [Full Text] [Related]

  • 4. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS.
    Oncotarget; 2016 Nov 08; 7(45):74380-74392. PubMed ID: 27602582
    [Abstract] [Full Text] [Related]

  • 5. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS.
    Cell Cycle; 2017 Oct 02; 16(19):1790-1799. PubMed ID: 28489985
    [Abstract] [Full Text] [Related]

  • 6. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
    Graves PR, Aponte-Collazo LJ, Fennell EMJ, Graves AC, Hale AE, Dicheva N, Herring LE, Gilbert TSK, East MP, McDonald IM, Lockett MR, Ashamalla H, Moorman NJ, Karanewsky DS, Iwanowicz EJ, Holmuhamedov E, Graves LM.
    ACS Chem Biol; 2019 May 17; 14(5):1020-1029. PubMed ID: 31021596
    [Abstract] [Full Text] [Related]

  • 7. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV, Allen JE, Dicker DT, El-Deiry WS.
    Cancer Res; 2015 Apr 01; 75(7):1423-32. PubMed ID: 25712124
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
    Jhaveri AV, Zhou L, Ralff MD, Lee YS, Navaraj A, Carneiro BA, Safran H, Prabhu VV, Ross EA, Lee S, El-Deiry WS.
    Cancer Biol Ther; 2021 Dec 02; 22(10-12):607-618. PubMed ID: 34856854
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.
    Bonner ER, Waszak SM, Grotzer MA, Mueller S, Nazarian J.
    Neuro Oncol; 2021 Apr 12; 23(4):542-556. PubMed ID: 33336683
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R, Zhou L, Chang WI, Zhang Y, Sharma A, Prabhu VV, Tapinos N, Lulla RR, El-Deiry WS.
    Am J Cancer Res; 2021 Apr 12; 11(9):4607-4623. PubMed ID: 34659909
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor.
    Free RB, Cuoco CA, Xie B, Namkung Y, Prabhu VV, Willette BKA, Day MM, Sanchez-Soto M, Lane JR, Laporte SA, Shi L, Allen JE, Sibley DR.
    Mol Pharmacol; 2021 Oct 12; 100(4):372-387. PubMed ID: 34353882
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
    Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.
    Cell Cycle; 2018 Oct 12; 17(4):468-478. PubMed ID: 29157092
    [Abstract] [Full Text] [Related]

  • 20. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK, Allen JE, Dicker DT, El-Deiry WS.
    Cell Cycle; 2015 Aug 03; 14(15):2422-8. PubMed ID: 26030065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.